Rheumatoid arthritis: vizsgálatok itt: Lengyelország
20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
- Where
- Cracow, Jozefow, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 56 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to join2024-519114-31-00 · EU 2024-519114-31-00 - 1. fázisTaking peopleA clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Jjp Biologics Sp. z o.o.
See details and how to join2023-508661-33-00 · EU 2023-508661-33-00 - 3. fázisNot yet taking people in LengyelországA Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
- Where
- Bydgoszcz, Nadarzyn, Olsztyn, Plonsk, Tomaszów Lubelski, Warsaw, Wroclaw, ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. Supronik
- Életkor
- 18 év and over
- People
- 266
- Run by
- Celltrion Inc.
See details and how to join2026-526538-15-00 · EU 2026-526538-15-00 - 1/2. fázisTaking peopleA Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
- Where
- Jozefow
- Életkor
- 18 év to 65 év
- People
- 84 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07412704 · EU 2025-520666-22-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
- Where
- Bytom, Elbl?g, Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07137598 - 2. fázisTaking peopleAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
- Where
- Bytom, Elblag, Lublin, Nowa Sol, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07620392 · EU 2025-523579-47-00 - 1. fázisNot yet taking people in LengyelországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Bydgoszcz, Krakow, Poznan
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
- Where
- Krakow, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07276581 - 2. fázisTaking peopleA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
- Where
- Bydgoszcz, Cracow, Elblag, Olsztyn, Warsaw
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT06972446 · EU 2025-520721-21-00 - 2. fázisTaking peopleA study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
- Where
- Cracow, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 97 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-522076-85-00 · EU 2025-522076-85-00 - 1. fázisTaking peopleStudy of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
- Where
- Torun, Warsaw
- Életkor
- 18 év to 75 év
- People
- 176 worldwide
- Run by
- Lifordi Immunotherapeutics, Inc.
See details and how to joinNCT07207954 - 2. fázisNot yet taking people in LengyelországA study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
- Where
- Bialystok, Cracow, Katowice, Łódź, Lublin, Oswiecim, Poznan, Sosnowiec, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 95 worldwide
- Run by
- Elevara Medicines Limited
See details and how to join2025-524005-32-00 · EU 2025-524005-32-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors
- Where
- Bytom, Elblag, Lublin, Nowa Sol, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 89 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2025-521034-28-00 · EU 2025-521034-28-00 - 1. fázisTaking peopleA study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
- Where
- Torun, Warsaw
- Életkor
- 18 év and over
- People
- 40
- Run by
- Lifordi Immunotherapeutics Inc.
See details and how to join2025-523409-13-00 · EU 2025-523409-13-00 - No phaseTaking peopleIntegrative AI-Based Multiomic and Neurophysiological Profiling of Chronic Pain in Rheumatoid Arthritis
- Where
- Wroclaw
- Életkor
- 18 év and over
- People
- 100
- Run by
- 4th Military Clinical Hospital with Polyclinic, Poland
See details and how to joinNCT07769619 - 1. fázisTaking peopleA First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
- Where
- Jozefow
- Életkor
- 18 év to 64 év
- People
- 15 worldwide
- Run by
- Neurocrine Biosciences Inc.
See details and how to join2025-525113-22-00 · EU 2025-525113-22-00 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Bydgoszcz, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Bytom, Gdansk, Gliwice, Lodz
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Cracow, Poznan, Warsaw
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - 2. fázisTaking peopleA Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
- Where
- Chorzów, Katowice, Poznan, Swidnica
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- SynAct Pharma Aps
See details and how to joinNCT06671054